Albuterol + Budesonide for Asthma

This trial tests a combination of two inhalers to assess their impact on lung function in people with asthma. Researchers aim to understand how these treatments might alter airflow in the lungs and enhance breathing. Participants will first use an albuterol inhaler, followed by a combined albuterol-budesonide inhaler. This trial suits adults diagnosed with asthma who have used a consistent dose of inhaled steroids for at least three months. As a Phase 4 trial, the research focuses on understanding how the already FDA-approved treatment can benefit more patients.

You need to have been on a steady dose of inhaled corticosteroids (ICS) for at least 3 months before joining the trial. You cannot use systemic glucocorticosteroids or oral methyl-xanthines within 30 days of the study visit.

Research shows that the combination of albuterol and budesonide, known as AIRSUPRA, is generally well-tolerated. Studies have found that this combination significantly reduces the risk of severe asthma attacks compared to albuterol alone, lowering the risk by up to 47%. Importantly, no major safety concerns have emerged with this treatment.

Researchers are excited about the combination of Albuterol and Budesonide for asthma because it offers a novel approach to managing the condition. Unlike standard treatments that typically involve using a bronchodilator like Albuterol alone, this combination also includes Budesonide, a corticosteroid, which helps in reducing inflammation in the airways. This dual action not only provides immediate relief by opening up the airways but also addresses the underlying inflammation, potentially offering more comprehensive asthma control. The use of a metered-dose inhaler with a spacer ensures effective delivery of both medications, which could improve the overall management of asthma symptoms.

Research has shown that using albuterol with budesonide helps reduce asthma flare-ups. One study showed that this combination lowered the risk of severe asthma attacks by 27% compared to albuterol alone. Another study found a 47% reduction in severe asthma flare-ups with this treatment. It also decreased the yearly number of severe episodes, proving its effectiveness. In this trial, participants will first receive Albuterol Sulfate, followed by the combination of Albuterol/Budesonide, allowing for a direct comparison of their effectiveness in managing asthma symptoms.⁶⁷⁸⁹¹⁰